DMAC vs MPLT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Momentum & Technical, Options & Structure while MPLT counters with relative strength in Growth & Margin. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MPLT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against MPLT sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | MPLT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $392.9M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -114.6% | -111.5% | Higher ROE | MPLT |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 3% ($6โ$40) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 1.05ฮฒ ยท 78% Vol | Lower Realized Risk | MPLT |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 50.4 / 100 (HOLD) | Higher Composite | MPLT |